All In Biotech

Drug Trial Radar · NCT00789737

Welchol as Monotherapy for Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Feb 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 357 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

357

Actual

Start

Jan 2009

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Nov 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • WelcholDrug

    Welchol 625mg tablets

  • PlaceboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Hemoglobin A1cTime frame: 24 week

Locations

107 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Muscle Shoals, Alabama

  • Site not named

    Green Valley, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Searcy, Arkansas

  • Site not named

    Buena Park, California

  • Site not named

    Burbank, California

  • Site not named

    Chula Vista, California

  • Site not named

    Garden Grove, California

  • Site not named

    Huntington Park, California

  • Site not named

    Irvine, California

  • Site not named

    La Mirada, California

  • Site not named

    Lincoln, California

  • Site not named

    Lomita, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Gatos, California

  • Site not named

    Santa Ana, California

  • Site not named

    Tustin, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Brooksville, Florida

  • Site not named

    Coral Gables, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Gulf Breeze, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Ormond Beach, Florida

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.